Acumen Pharmaceuticals is focused on developing targeted therapies for Alzheimer's disease, particularly through their advanced candidate, sabirnetug (ACU193), which targets toxic soluble amyloid beta oligomers
Acumen Pharmaceuticals is focused on developing targeted therapies for Alzheimer's disease, particularly through their advanced candidate, sabirnetug (ACU193), which targets toxic soluble amyloid beta oligomers.